Imutdol-P Tablet is a combination analgesic formulation containing Tramadol hydrochloride 37.5 mg and Paracetamol 325 mg, designed for the management of moderate to moderately severe pain. Tramadol, a centrally acting synthetic opioid analgesic, exerts its effect by binding to the mu-opioid receptor and inhibiting the reuptake of norepinephrine and serotonin, thereby modulating pain perception. Paracetamol, a widely used non-opioid analgesic and antipyretic agent, acts primarily through central inhibition of prostaglandin synthesis, contributing to its analgesic and antipyretic properties. The synergistic combination in Imutdol-P provides enhanced analgesia while potentially reducing the required dose of tramadol, thereby minimizing opioid-related adverse effects. This tablet is indicated for conditions such as postoperative pain, musculoskeletal pain, osteoarthritis, and other painful conditions where moderate analgesia is required. Imutdol-P should be administered as per physician’s guidance, with careful consideration of contraindications including hypersensitivity to either component, severe respiratory depression, and acute intoxication with alcohol or central nervous system depressants. Caution is advised in patients with hepatic or renal impairment, history of seizures, or those on concomitant serotonergic drugs due to the risk of serotonin syndrome. Adverse effects may include nausea, dizziness, constipation, and somnolence. Proper patient counseling and adherence to prescribed dosage are essential to optimize therapeutic outcomes and minimize risks.